Microbix Biosystems Inc MBXBF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 136.97M
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 189.75
- Price/Sales
- 2.66
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 1.89%
Company Profile
Microbix Biosystems Inc develops biological products and technologies. There are two operating segments: The development, manufacturing, and sale of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows, and viral transport medium to enable collection of patient test samples; and the development and commercialization of novel and proprietary products or technologies such as Kinlytic. Geographically, it derives a majority of revenue from North America and also operates in Europe and other foreign countries.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 130
- Website
- https://www.microbix.com
Valuation
|
Metric
|
MBXBF
|
|---|---|
Price/Earnings (Normalized) | 189.75 |
Price/Book Value | 1.91 |
Price/Sales | 2.66 |
Price/Cash Flow | — |
Price/Earnings
MBXBF
Financial Strength
|
Metric
|
MBXBF
|
|---|---|
Quick Ratio | 3.17 |
Current Ratio | 6.89 |
Interest Coverage | −4.14 |
Quick Ratio
MBXBF
Profitability
|
Metric
|
MBXBF
|
|---|---|
Return on Assets (Normalized) | −11.77% |
Return on Equity (Normalized) | −17.56% |
Return on Invested Capital (Normalized) | −10.57% |
Return on Assets
MBXBF
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|$dyzLcX | LOCK|SvY& | $129B | |||
| Moderna Inc
MRNA
| LOCK|<RwzCN | LOCK|<&v | $90B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|^swt?S> | LOCK|!p$F | $77B | |||
| argenx SE ADR
ARGX
| LOCK|&P&mBw | LOCK|LR | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|r%L@^> | LOCK|d$y | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|%fGF??C | LOCK|bf!d | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|$T%@M?! | LOCK|>#>?# | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|@<%rJBZ | LOCK|sb | $24B | |||
| Incyte Corp
INCY
| LOCK|@!&xBD | LOCK|%>^ | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|%<NcST | LOCK|LM | $14B |
United States